CA2221821A1 - Polypeptide de type iii activateur des monocytes et des cellules endotheliales - Google Patents

Polypeptide de type iii activateur des monocytes et des cellules endotheliales Download PDF

Info

Publication number
CA2221821A1
CA2221821A1 CA002221821A CA2221821A CA2221821A1 CA 2221821 A1 CA2221821 A1 CA 2221821A1 CA 002221821 A CA002221821 A CA 002221821A CA 2221821 A CA2221821 A CA 2221821A CA 2221821 A1 CA2221821 A1 CA 2221821A1
Authority
CA
Canada
Prior art keywords
polypeptide
polynucleotide
dna
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002221821A
Other languages
English (en)
Inventor
Timothy A. Coleman
Henrik S. Olsen
Craig A. Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002221821A priority Critical patent/CA2221821A1/fr
Publication of CA2221821A1 publication Critical patent/CA2221821A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Abstract

L'invention concerne un polypeptide, d'origine humaine, de type III, activateur des monocytes et des cellules endothéliales(EMAP III) ainsi que l'ADN (ARN) codant ce type de polypeptides. L'invention concerne également un mode opératoire de production d'un tel polypeptide par des techniques de recombinaison ainsi que des procédés d'utilisation d'un tel polypeptide aux fins de la prévention et/ou du traitement de la néoplasie. L'invention concerne en outre des procédés de diagnostic permettant d'une part, d'identifier des mutations dans la séquence d'acides nucléiques codant ce polypeptide et d'autre part, de déceler des modifications de la concentration de ce polypeptide associées à des maladies telles que le cancer.
CA002221821A 1995-06-07 1995-06-07 Polypeptide de type iii activateur des monocytes et des cellules endotheliales Abandoned CA2221821A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002221821A CA2221821A1 (fr) 1995-06-07 1995-06-07 Polypeptide de type iii activateur des monocytes et des cellules endotheliales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002221821A CA2221821A1 (fr) 1995-06-07 1995-06-07 Polypeptide de type iii activateur des monocytes et des cellules endotheliales
PCT/US1995/007328 WO1996040719A1 (fr) 1995-06-07 1995-06-07 Polypeptide de type iii activateur des monocytes et des cellules endotheliales

Publications (1)

Publication Number Publication Date
CA2221821A1 true CA2221821A1 (fr) 1996-12-19

Family

ID=22249285

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002221821A Abandoned CA2221821A1 (fr) 1995-06-07 1995-06-07 Polypeptide de type iii activateur des monocytes et des cellules endotheliales

Country Status (5)

Country Link
EP (1) EP0873349A4 (fr)
JP (1) JP3759168B2 (fr)
AU (1) AU2821695A (fr)
CA (1) CA2221821A1 (fr)
WO (1) WO1996040719A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885798A (en) * 1996-08-28 1999-03-23 Incyte Pharmaceuticals, Inc. DNA encoding a monocyte activating cytokine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641867A (en) * 1993-09-29 1997-06-24 The Trustees Of Columbia University In The City Of New York Antibody which specifically binds to endothelial-monocyte activating polypeptide II

Also Published As

Publication number Publication date
EP0873349A4 (fr) 2001-03-14
JP3759168B2 (ja) 2006-03-22
AU2821695A (en) 1996-12-30
WO1996040719A1 (fr) 1996-12-19
EP0873349A1 (fr) 1998-10-28
JPH11507506A (ja) 1999-07-06

Similar Documents

Publication Publication Date Title
US7482326B2 (en) Endothelial-monocyte activating polypeptide III
US7160546B2 (en) Human G-protein chemokine receptor (CCR5) HDGNR10
US20070154908A1 (en) Connective Tissue Growth Factor-2
US7132509B2 (en) Colon specific gene and protein
US5861272A (en) C5A receptor
AU711346B2 (en) Colon specific gene and protein
US20060148708A1 (en) C5a receptor
CA2242633A1 (fr) Facteur transformant de croissance alpha hiii
US5650313A (en) Ubiquitin conjugating enzymes 8 and 9
US20050123998A1 (en) C5a receptor
WO1996039424A1 (fr) Facteur c stimulant les cellules tueuses naturelles
US5849286A (en) Ubiquitin conjugating enzymes 7,8 and 9
US7083930B2 (en) Human choline acetyltransferase
CA2215350C (fr) Facteur de croissance transformant alpha hii
US20030143227A1 (en) Immune cell cytokine
WO1996039485A1 (fr) Facteur de croissance de type 2 derive de l'hepatome humain
AU752206B2 (en) Extracellular/epidermal growth factor like protein
WO1997018224A1 (fr) Antigene 2 de cellules-souches humaines
US6255079B1 (en) Polynucleotides encoding natural killer cell enhancing factor C
CA2221821A1 (fr) Polypeptide de type iii activateur des monocytes et des cellules endotheliales
AU716415B2 (en) Pineal gland specific gene-1
US20020119487A1 (en) Human stem cell antigen 2
AU753309B2 (en) Pineal gland specific gene-1
US6482922B2 (en) Mammary transforming protein
US20050181477A1 (en) Extracellular/epidermal growth factor like protein

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead